Tybjaerg-Hansen A, Steffensen R, Meinertz H, Schnohr P, Nordestgaard B G
Department of Clinical Biochemistry, Herlev University Hospital, University of Copenhagen, Denmark.
N Engl J Med. 1998 May 28;338(22):1577-84. doi: 10.1056/NEJM199805283382203.
Familial hypercholesterolemia leads to premature ischemic heart disease and is often caused by mutations in the gene for the low-density lipoprotein receptor. Mutations in the apolipoprotein B gene, which encodes a ligand for this receptor, may also result in this phenotype.
We studied the genotypes of 9255 women and men from the general population, 948 patients with ischemic heart disease, and 36 patients with familial hypercholesterolemia, all from Denmark, for three mutations in the apolipoprotein B gene: Arg3500Gln, Arg3531Cys, and Arg3500Trp.
The prevalence of heterozygotes in the general population was 0.08 percent (95 percent confidence interval, 0.03 to 0.16 percent) for both the Arg3500Gln and the Arg3531Cys mutations, and 0.00 percent (95 percent confidence interval, 0.00 to 0.18 percent) for the Arg3500Trp mutation. Among carriers of the Arg3500Gln mutation, cholesterol levels were significantly higher than among noncarriers in the general population - by 100 mg per deciliter (2.6 mmol per liter) among carriers in the general population, 154 mg per deciliter (4.0 mmol per liter) among patients with ischemic heart disease, and 172 mg per deciliter (4.5 mmol per liter) among patients with familial hypercholesterolemia. Heterozygous carriers of the Arg3500Gln mutation were significantly more common among patients with ischemic heart disease (odds ratio, 7.0; 95 percent confidence interval, 2.2 to 22; P=0.003) and patients with familial hypercholesterolemia (odds ratio, 78; 95 percent confidence interval, 16 to 388; P=0.001) than in the general population. Heterzygous carriers of the Arg3531Cys mutation in the general population did not have higher-than-normal plasma cholesterol levels or an increased risk of ischemic heart disease (odds ratio; 1.4; 95 percent confidence interval, 0.2 to 11; P=0.54).
The Arg3500Gln mutation in the apolipoprotein B gene, which is responsible for familial defective apolipoprotein B-100 and is present in approximately 1 in 1000 persons in Denmark, causes severe hypercholesterolemia and increases the risk of ischemic heart disease.
家族性高胆固醇血症会导致过早发生缺血性心脏病,通常由低密度脂蛋白受体基因的突变引起。编码该受体配体的载脂蛋白B基因的突变也可能导致这种表型。
我们研究了来自丹麦普通人群的9255名女性和男性、948例缺血性心脏病患者以及36例家族性高胆固醇血症患者的载脂蛋白B基因的三种突变:Arg3500Gln、Arg3531Cys和Arg3500Trp。
在普通人群中,Arg3500Gln和Arg3531Cys突变的杂合子患病率均为0.08%(95%置信区间为0.03%至0.16%),Arg3500Trp突变的患病率为0.00%(95%置信区间为0.00%至0.18%)。在Arg3500Gln突变携带者中,胆固醇水平显著高于普通人群中的非携带者——普通人群中的携带者胆固醇水平高出100毫克/分升(2.6毫摩尔/升),缺血性心脏病患者高出154毫克/分升(4.0毫摩尔/升),家族性高胆固醇血症患者高出172毫克/分升(4.5毫摩尔/升)。Arg3500Gln突变的杂合子携带者在缺血性心脏病患者(优势比为7.0;95%置信区间为2.2至22;P = 0.003)和家族性高胆固醇血症患者(优势比为78;95%置信区间为16至388;P = 0.001)中比在普通人群中更为常见。普通人群中Arg3531Cys突变的杂合子携带者血浆胆固醇水平没有高于正常水平,也没有增加缺血性心脏病的风险(优势比为1.4;95%置信区间为0.2至11;P = 0.54)。
载脂蛋白B基因中的Arg3500Gln突变导致家族性缺陷载脂蛋白B - 100,在丹麦约每1000人中就有1人携带,会导致严重的高胆固醇血症并增加缺血性心脏病的风险。